文献类型：期刊文献

英文题名：Clinical efficacy and safety of proton radiotherapy for ocular conjunctival malignancies: a systematic review and meta-analysis

作者：Zheng, Tingwei[1,2];Wang, Dandan[3];Miao, Yuxin[1,2];Dong, Meng[3];Liu, Qin[1,2];Zhang, Qiuning[3];Bai, Huiling[1,2];Luo, Hongtao[4];Li, Meixuan[5]

第一作者：Zheng, Tingwei

通信作者：Bai, HL[1];Bai, HL[2];Luo, HT[3]

机构：[1]Gansu Univ Chinese Med, Sch Clin Med 1, Lanzhou, Gansu, Peoples R China;[2]Gansu Prov Hosp, Lanzhou, Gansu, Peoples R China;[3]Chinese Acad Sci, Inst Modern Phys, Lanzhou, Peoples R China;[4]Gansu Prov Hosp TCM, Lanzhou, Gansu, Peoples R China;[5]Lanzhou Univ, Evidence Based Med Ctr, Sch Basic Med Sci, Lanzhou, Gansu, Peoples R China

第一机构：甘肃中医药大学

通信机构：[1]corresponding author), Gansu Univ Chinese Med, Sch Clin Med 1, Lanzhou, Gansu, Peoples R China;[2]corresponding author), Gansu Prov Hosp, Lanzhou, Gansu, Peoples R China;[3]corresponding author), Gansu Prov Hosp TCM, Lanzhou, Gansu, Peoples R China.|[10735]甘肃中医药大学;

年份：2025

卷号：13

外文期刊名：FRONTIERS IN PUBLIC HEALTH

收录：;Scopus(收录号：2-s2.0-85219555747);WOS:【SSCI(收录号:WOS:001432256400001)，SCI-EXPANDED(收录号:WOS:001432256400001)】；

基金：The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was supported by the Science and Technology Plan Project of Gansu Province (23JRRA1291), the National Key Research and Development Program of China (No. 2022YFC2401500), Talent Innovation and Venture Project of Lanzhou City (2020-RC-113), the Central Guidance Local Science and Technology Development Program (Grant No. 24ZYQA029), the Science and Technology Project of Lanzhou City (Grant No. 2023-1-9), Gansu Province Project of Science and Technologies (Grant No. 20JR10RA680, 22CX8JA149), and the Lanzhou Heavy Ion Accelerator High-End User Project (HIR20GY007).

语种：英文

外文关键词：proton beam therapy; ocular conjunctival malignancies; systematic review; meta-analysis; effectiveness and safety

摘要：Objective: The use of proton beam therapy (PBT) for treating ocular conjunctival malignancies is on the rise across numerous medical centers. This study conducts a systematic review and meta-analysis to assess the effectiveness and safety of PBT in treating malignant conjunctival tumors. Methods: We searched for studies on PBT for ocular conjunctival malignancies in PubMed, Embase, Cochrane Library, and Web of Science (WoS) databases up to November 25, 2023. Studies were selected and data were extracted by two independent reviewers based on pre-established inclusion and exclusion criteria. The quality of evidence was assessed using the GRADE method. Meta-analysis was performed using STATA version 16.0. Results: An initial search yielded 586 articles, from which six retrospective case series studies were selected involving 291 patients with ocular conjunctival malignancies, including 240 cases of conjunctival melanoma and 51 cases of conjunctival squamous cell carcinoma (SCC). Meta-analysis with a random-effects model showed that PBT is effective and relatively safe, with 2-, 4-, and 5-year overall survival (OS) rates of 98% (95% CI 95-102%), 87% (95% CI 69-104%), and 78% (95% CI 70-87%) respectively. Reported toxicity rates included 19% for cataracts, 10% for glaucoma, 5% for lacrimal stenosis, 52% for sicca symptoms, and 11% for limbal stem cell deficiency. The GRADE assessment yielded a low certainty of evidence. Conclusions: Proton therapy offers a viable alternative treatment for patients with conjunctival malignancies, with acceptable treatment-related toxicity rates.